Targeted Therapy: Rapid Advances Change the Paradigm in Bladder Cancer

A greater understanding of not only tumor biology and driver mutations but also targeted therapy has led to unprecedented precision and efficacy in treating bladder cancer.

FDA grants accelerated approval to erdafitinib for metastatic urothelial carcinoma

FDA grants accelerated approval to enfortumab vedotin-ejfv for metastatic urothelial cancer

Read More